By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More
Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More
The Genie in the Test Tube - From Gene to Gene Therapy: Part 2 By Dr Jan Steiner In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of… Read More
Drug Delivery - Adding value to drug development and commercialisation By Dr Cornelis 'Cees' Winnips The importance of drug delivery as a tool to improve R&D productivity, to provide a pathway for valuable drugs to be successfully commercialised and as an expanding resource to the pharmaceutical and biotech industry, has… Read More
By Michael P. Murphy, MSc Pharmacogenomics offers the opportunity to adopt a new paradigm in drug development. The pharmaceutical industry is faced with a number of challenges including relatively low productivity and success in bringing new drugs to market. Investors demand that pharmaceutical companies deliver several new drugs to the… Read More
The Genie in the Test Tube - From Gene to Gene Therapy: Part 1 By Dr Jan Steiner For thousands of years, medicine was a descriptive art, with treatments for disease arising from astute observation and trial and error. The rise of modern forms of biological sciences, especially the developments… Read More
Emerging therapeutic vaccines By Marc Hertz, Soren Mouritsen and Anand Gautam The excitement over the past 30 years for immunotherapy of cancer and other diseases has not led to the expected clinical successes. Over-enthusiasts predicted a cure for cancer with the initial development of monoclonal antibody technology, and later the… Read More